1. Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial 
Dr Pedro A de Alarcon, MD, Katherine K Matthay, MD, Wendy B London, PhD, Arlene Naranjo, PhD, Sheena C Tenney, MSPH, Jessica A Panzer, MD, Michael D Hogarty, MD, Julie R Park, MD, John M Maris, MD, Susan L Cohn, MD 
The Lancet Child & Adolescent Health 
Volume 2, Issue 1, Pages (January 2018)
DOI: /S (17)30130-X
Copyright © 2018 Elsevier Ltd Terms and Conditions

2. Figure 1
Study design
IVIG=intravenous immunoglobulin. ACTH=adrenocorticotropic hormone. OMA=opsoclonus myoclonus ataxia syndrome. *OMA evaluation timepoints include: at diagnosis, monthly for 6 months, then every other month until 1 year, 18 months, 2 years, and once per year thereafter up to 10 years.
The Lancet Child & Adolescent Health 2018 2, 25-34DOI: ( /S (17)30130-X)
Copyright © 2018 Elsevier Ltd Terms and Conditions

3. Figure 2
Trial profile
IVIG=intravenous immunoglobulin. ACTH=adrenocorticotropic hormone. OMA=opsoclonus myoclonus ataxia syndrome. *Parent refused further treatment.
The Lancet Child & Adolescent Health 2018 2, 25-34DOI: ( /S (17)30130-X)
Copyright © 2018 Elsevier Ltd Terms and Conditions

4. Figure 3
Neuroblastoma event-free, OMA progression-free, and overall survival of patient cohort
NBL=neuroblastoma. EFS=event free survival. OMA=opsoclonus myoclonus ataxia syndrome. PFS=progression free survival. OS=overall survival.
The Lancet Child & Adolescent Health 2018 2, 25-34DOI: ( /S (17)30130-X)
Copyright © 2018 Elsevier Ltd Terms and Conditions

5. Figure 4 OMA progression-free survival for IVIG and no IVIG groups
OMA=opsoclonus myoclonus ataxia syndrome. IVIG=intravenous immunoglobulin.
The Lancet Child & Adolescent Health 2018 2, 25-34DOI: ( /S (17)30130-X)
Copyright © 2018 Elsevier Ltd Terms and Conditions